RxDoctor Payments Data

Salvador Murra, MD

Neurology · Houston, TXNPI 1962481838

Payments from drug & device makers

$5,313in general payments, 2019–2025

Across 267 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurelis, Inc.$828
  • UCB, Inc.$701
  • Eisai Inc.$417
  • Sunovion Pharmaceuticals Inc.$396
  • EMD Serono, Inc.$281
  • AbbVie$280
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,23398%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,313 in reported general payments places this provider in the 55th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$51,864
Medicare patients
103
Services billed
276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab11$132,187
AptiomEslicarbazepine Acetate24$42,485
XcopriCenobamate36$40,725
FycompaPerampanel26$32,732
Oxtellar XrOxcarbazepine11$29,913
BriviactBrivaracetam16$25,783
ValtocoDiazepam29$23,280
Levetiracetam312$16,846
Lacosamide131$16,678
ImitrexSumatriptan Succinate13$7,114
Divalproex Sodium62$6,328
Carbamazepine ErCarbamazepine29$4,658
Oxcarbazepine34$4,594
Zonisamide98$4,416
Carbidopa-LevodopaCarbidopa/Levodopa199$4,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$396$42,48524 claims
SK Life Science, Inc.Xcopri$211$40,72536 claims
Eisai Inc.Fycompa$417$32,73226 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$227$29,91311 claims
UCB, Inc.Briviact$701$25,78316 claims
Neurelis, Inc.Valtoco$828$23,28029 claims
Lilly USA, LLCOlanzapine$58$29616 claims
Almatica Pharma LLCSertraline Hcl$30$26961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →